U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07492628) titled 'Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma' on March 20.
Brief Summary: This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally advanced or metastatic urothelial carcinoma. Based on public urothelial-cancer evidence, Nectin-4 was selected as the lead antigen because it has the strongest disease-specific clinical validation; HER2/ERBB2 was chosen as the secondary co-target to broaden tumor coverage and reduce antigen-escape risk. EpC...